Year-end Sale % OFF 
Abstract
The systemic hemostatic and hemostasiological effects of intravenous injection of fibrin monomer (FM; 0.25 mg/kg) together with dabigatran etexilate (15-20 mg/kg) administration were compared to placebo (0.5 ml), prothrombin complex concentrate (d = 40 U/kg) and Eptacog alfa (activated) (d = 270 μg/kg) in a model of a controlled liver injury in 62 rabbits of the Chinchilla breed. It was found that FM, in comparison to placebo, reduced the volume of blood loss by 2.9 times and the rate of blood loss by 1.7 times, despite the dabigatran-induced hypocoagulation. Comparators did not show hemostatic efficacy. FM did not affect the parameters of the coagulogram (no visible hemostasiological effect), while the compared drugs showed some signs of increased hemostatic potential. It is assumed that the hemostatic effects of low, physiological doses of FM can be realized bypassing thrombin (factor IIa), which determines the need for further studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
